دورية أكاديمية
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
| العنوان: | Idecabtagene vicleucel in relapsed and refractory multiple myeloma |
|---|---|
| المؤلفون: | Munshi, Nikhil C., Anderson, Larry D., Shah, Nina, Madduri, Deepu, Berdeja, Jesus, Lonial, Sagar, Raje, Noopur, Lin, Yi, Siegel, David, Oriol, Albert, Moreau, Philippe, Yakoub-Agha, Ibrahim, Delforge, Michel, Cavo, Michele, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Rambaldi, Alessandro, Reece, Donna, Petrocca, Fabio, Massaro, Monica, Connarn, Jamie N., Kaiser, Shari, Patel, Payal, Huang, Liping, Campbell, Timothy B., Hege, Kristen, San-Miguel, Jesus |
| المساهمون: | CHU Lille, Inserm, Université de Lille, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286 |
| سنة النشر: | 2024 |
| المجموعة: | LillOA (Lille Open Archive - Université de Lille) |
| الوصف: | Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma. Patients with disease after at least three previous regimens including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody were enrolled. Patients received ide-cel target doses of 150 × 1066 Of 140 patients enrolled, 128 received ide-cel. At a median follow-up of 13.3 months, 94 of 128 patients (73%) had a response, and 42 of 128 (33%) had a complete response or better. Minimal residual disease (MRD)-negative status (<10-5 Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.). ; 384 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/octet-stream |
| اللغة: | English |
| العلاقة: | The New England journal of medicine; N Engl J Med; http://hdl.handle.net/20.500.12210/40646Test |
| الإتاحة: | https://doi.org/20.500.12210/40646Test https://hdl.handle.net/20.500.12210/40646Test |
| رقم الانضمام: | edsbas.CBE6E983 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |